Finally, in a PDX model of AML cells harboring MLL-AF9 and FLT3 mutation, co-treatment with ziftomenib and venetoclax or OTX015 yielded significantly greater reduction in AML burden and improvement in survival compared to each agent alone without significant host toxicity. This evidence concerns the gene KMT2A and acute myeloid leukemia.